We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Can Determine Liver Disease Progression

By LabMedica International staff writers
Posted on 22 Jun 2022

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide and is estimated to affect about 30% of the European population. More...

Chronic non-alcoholic fatty liver disease can develop into irreversible liver cirrhosis, which can only be cured by liver transplantation. Therefore, it is particularly important to identify patients with non-alcoholic fatty liver disease early on. Now, researchers have identified the role of a specific subtype of macrophages (white blood cells) in progressive NAFLD. As part of the immune system, these cells have a protective function against fibrosis and liver cirrhosis. At the same time, they are useful as biomarkers of liver disease progression as they can be measured by a blood test.

The pathogenesis (development) of NAFLD, especially advanced steatohepatitis (NASH, also: non-alcoholic fatty liver hepatitis), is associated with profound changes in immune cells in the liver. Recently, the increased accumulation of a subtype of macrophages that express high levels of the receptor TREM2 has been described in fatty liver disease. However, the role of TREM2-positive macrophages in non-alcoholic fatty liver disease was hitherto unknown. Now, researchers at Medical University Vienna (Vienna, Austria) have shown in an animal model that these specific macrophages have a protective function in fibrosis - a precursor to liver cirrhosis. These cells are found in greater numbers in the affected areas of the liver upon NAFLD-associated liver inflammation, where they accumulate particularly in areas of cellular damage and fibrosis.

TREM2 exists both as a membrane receptor on cells as well as a soluble form (sTREM2) that is detectable in blood. The role of this soluble form in the immune system is not yet clear. However, the researchers discovered that it is useful in patients for determining the current status of the disease and helps to distinguish between the different stages of fatty liver hepatitis much better than previously known biomarkers used in clinical practice. The researchers also demonstrated in bone marrow transplantation models that hematopoietic TREM2 deficiency prevents efficient fat storage and breakdown of excess connective tissue (extracellular matrix), leading to increased steatohepatitis, cell death and fibrosis. Hence, TREM2-positive macrophages fulfill an important protective function in NAFLD, where they prevent fat accumulation, inflammatory processes and progression of the disease to liver fibrosis.

"It may be possible to develop new therapeutic approaches to treat fatty liver hepatitis by enhancing this protective function of TREM2-positive macrophages," said Florentina Porsch, co-first author of the study.

"The soluble form of TREM2 is an excellent biomarker for identifying and staging advanced liver disease, which can progress from fatty liver disease to incurable cirrhosis if left untreated," added first author Tim Hendrikx from MedUni Vienna's Department of Laboratory Medicine.

Related Links:
Medical University Vienna 


New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.